If this message does not display properly, please click here to launch your browser.
|
Based on our Pharmacor Venous Thromboembolism advisory service, Decision Resources is offering an exclusive analyst call entitled Venous Thromboembolism: How Will Sanofi-Aventis’s Semuloparin (AVE-5026) Compete in a Market That Will Soon Feature a Range of Oral Anticoagulants? Because this presentation will feature major updates, it is ONLY available to purchasers of this Pharmacor advisory service. Please contact us to learn how you can purchase this Pharmacor advisory service and attend the analyst call. The introduction of a range of novel oral anticoagulants with vastly superior therapeutic profiles over warfarin will revolutionize the prevention and treatment of venous thromboembolism (VTE) and will drive significant expansion of the market. In sharp contrast to the rich pipeline of oral anticoagulants, Sanofi-Aventis’s semuloparin represents the only late-stage parenteral agent in development for VTE indications. Phase III clinical trial data for semuloparin that were recently presented at the 21st International Congress of Thrombosis demonstrated the drug’s effectiveness and relative safety. This 15-minute analyst call, presented by Decision Resources Analyst Matthew Killeen, Ph.D., will answer the following questions:
Dr. Killeen will conduct a live Q & A session after the presentation. Registration Venous Thromboembolism: How Will Sanofi-Aventis’s Semuloparin (AVE-5026) Compete in a Market That Will Soon Feature a Range of Oral Anticoagulants? July 26, 2010 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris). To learn how you can purchase this Pharmacor advisory service and attend the analyst call, please contact us using the information below. In North America — Keith Rourke at 781-296-2656 or krourke@dresources.com |
|
||||
Terms of Use | Privacy Policy | Contact Us | Careers |
|||||
Matthew Killeen, Ph.D., is an Analyst on the cardiovascular and metabolic disorders team at Decision Resources. Prior to joining the company, Dr. Killeen worked in life sciences business development for the London Technology Network and in neuroscience drug discovery at Eli Lilly. He has also held research fellowships at Harvard Medical School and the Massachusetts General Hospital, where he studied the genetic basis of sudden cardiac death. Dr. Killeen is the author of 19 peer-reviewed journal articles on topics including sudden cardiac death, atrial fibrillation, cardiac drug safety, and mechanisms underlying cardiac arrhythmias. Dr. Killeen holds a Ph.D. in Physiology from Cambridge University and a B.Sc. (first class) in Pharmacology from the University of Leeds.